Pro-life leaders tore into a Justice Department status report that laid out the Food and Drug Administration’s timeline and data plan for a long-promised safety review of the abortion drug mifepristone, calling the effort inadequate and delayed. Just the News reported the filing went to U.S. District Judge David Joseph in Louisiana litigation challenging relaxed prescribing rules.
The report said the FDA is on track to obtain study results by mid-December 2026, then review those results and draft a report not later than March 2027. At that point, the agency anticipates it will be able to provide an update on whether and how it will revise the Risk Evaluation and Mitigation Strategy, or REMS, for mifepristone.
That schedule lands months after a federal court last spring gave the FDA six months to prove progress on the review or face the possible reimposition of restrictions, including in-person dispensing. The fight sits at the center of how widely the two-drug abortion regimen remains available by mail and without the older clinical safeguards.
The Justice Department told the court the FDA completed a feasibility assessment on whether enough exposures and outcomes exist across relevant time periods. Officials settled on 100,000 women in the mifepristone group and 100,000 in a comparator group.
The planned comparison measures the two-drug cocktail’s profile against surgical abortion through 70 days gestation. Analysts will use TreeScan statistical data mining to discover unknown safety concerns, if any.
The agency said it is drawing on a variety of data sources inside the Sentinel 2.0 distributed database and continues to gather and analyze additional data outside that system. It is also reviewing multiple pending citizen petitions, with hundreds of public comments already submitted.
Health and Human Services Secretary Robert F. Kennedy Jr. has described the effort as a “gold-standard study.” FDA Commissioner nominee Heidi Overton pledged to Senate Republicans that the work would be done “in the most durable scientific way possible and the results communicated transparently.”
Susan B. Anthony Pro-Life America President Marjorie Dannenfelser said the status report made no mention of commercial databases or crucial Medicaid data. She branded the supposed gold-standard project “fool’s gold.”
Dannenfelser warned that even if the FDA later restricts conditions in a revised REMS, the delay still translates to 90,000 mifepristone-enabled abortions in states that ban the pill by the end of March. She said the administration is leaving more women “vulnerable to coercion and abuse because basic medical oversight is absent.”
Live Action President Lila Rose hit the March 2027 completion target and the lack of any deadline for action on the REMS itself. In an email blast she wrote:
"This delay is UNACCEPTABLE."
She added a direct demand:
"The FDA must pull the abortion pill from the market NOW."
The current review follows years of loosened controls. In 2016 the FDA removed mandatory reporting of non-fatal adverse events from the mifepristone REMS, a change tied to what the agency treated as a clean multi-year safety record.
In 2023 the agency made permanent the elimination of the in-person dispensing requirement, converting a COVID-19 emergency order into standing policy. The 5th U.S. Circuit Court of Appeals blocked that 2023 change, but the Supreme Court repeatedly blocked the 5th Circuit’s mifepristone orders.
Last month, 5th Circuit judges were described as limited in what they could do without being overturned again until the full district court proceeding ends. The FDA also faces two court orders to reconsider the 2023 REMS in separate abortion-rights challenges that cast the remaining conditions as still too strict.
Obama-era FDA action earlier expanded the labeled usage window from 49 days, the same 70-day horizon now used as the surgical comparator in the new study design.
Live Action pointed to a peer-reviewed paper in Issues in Law and Medicine, a journal operated by the Alliance for Hippocratic Medicine and authored by Charlotte Lozier Institute scholars. The paper argues studies the FDA cited in 2016 do not adequately reflect real-world conditions because most included in-person exams, bloodwork, or ultrasounds unlikely to occur in online prescribing.
The authors alleged possible bias, saying the FDA largely excluded input from groups worried about pill safety while relying on letters, clinical guidance, and other material from groups with financial or political incentives to support a weaker REMS.
They also wrote that providers frequently told women to misrepresent their experience as a miscarriage if seeking treatment after taking mifepristone. That gap in complication reporting and miscoding, the paper said, left regulators dependent on voluntary reports that fail to detect many real-world harms, even as the agency justified REMS changes by citing a limited number of complication reports.
The Alliance for Hippocratic Medicine was the first major legal challenger to the mifepristone regimen. After that challenge failed on standing, red states stepped in with their own suits. Mail delivery of the pills remains a core complaint for those states, which say shipments functionally circumvent state bans.
Judge Joseph’s six-month clock forced the Justice Department to describe sources and timing after what critics called nearly a year of vague assurances. The new filing gives a concrete calendar: study results by mid-December 2026 and a drafted safety-review report by March 2027, with an expected update then on any REMS revision.
Susan B. Anthony Pro-Life America has tied the Louisiana case to midterm turnout, warning Republican enthusiasm will suffer unless the litigation is settled by restoring in-person dispensing. A Reuters-Ipsos six-day poll ending Monday found only 30% of Trump’s 2024 voters “very enthusiastic” about voting in the midterms, compared with 48% of Kamala Harris’s voters.
Ordinary enthusiasm ran 21% among Trump voters and 18% among Harris voters. Seventy-six percent of Harris backers said they are likely to vote, versus 63% of Trump’s backers. The poll carried a margin of error of 3 percentage points. Political analyst Charlie Cook termed the broader climate a “red undertow” rather than a blue wave.
Dannenfelser’s organization has played a major financial role in recent election cycles and continues to press the administration on medically supervised dispensing. Rose publicly abandoned Trump’s re-election bid in 2024, underscoring fractures among some advocacy groups over pace and priorities even after first-term judicial appointments helped end federal constitutional abortion rights.
Authorities have not publicly confirmed in the status report whether commercial claims databases or Medicaid records will be part of the core analysis. Investigators have not said when, if ever, the agency will act on the pending citizen petitions that seek reinstatement of removed safeguards such as in-person dispensing.
No public results have been released from the 100,000-per-arm Sentinel study. The FDA has not announced whether TreeScan findings, outside data, or the petition docket will drive REMS changes before or only after the March 2027 report.
Procedurally, the Louisiana case still turns on whether the agency can show genuine progress sufficient to avoid judicial reimposition of older controls. Parallel orders requiring reconsideration of the 2023 REMS keep the same drug under pressure from opposite legal theories at once.
For readers tracking federal drug policy, the next hard dates are mid-December 2026 for raw study results and March 2027 for the written safety review and any accompanying REMS update. Until then, the mail-order framework built in 2023 remains the operative national baseline unless a court orders otherwise.
When federal agencies stretch safety reviews past election calendars while mail-order abortion drugs stay widely available, voters are left to judge whether process is protecting patients or protecting a policy.
